Lymphoma Clinical Trials in Boston

Showing 421-440 of 451 trials

Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma

NCT00003741

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients with refractory anaplastic large cell lymphoma or Hodgkin's lymphoma.

Lymphoma

Beth Israel Deaconess Medical CenterStarted Feb 1999

Boston, Massachusetts, United States

COMPLETEDPhase 2< 1 mile

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00045539

RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with thiotepa in treating patients who have newly-diagnosed primary CNS lymphoma.

Lymphoma

New Approaches to Brain Tumor Therapy ConsortiumStarted Oct 2002

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +6 more locations

COMPLETEDPhase 2< 1 mile

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

NCT00006345

RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.

Drug/Agent Toxicity by Tissue/OrganLymphoma

Ligand PharmaceuticalsStarted Nov 1999

Miami, Florida, United States • Chicago, Illinois, United States • New Orleans, Louisiana, United States +8 more locations

Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Lymphoma Trials in Other Cities

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Other Conditions in Boston